Publication Name	World Journal of Gastroenterology
Manuscript ID	33711
Country	China

Received	2017-02-27 09:42
Peer-Review Started	2017-02-27 11:03
To Make the First Decision	2017-04-10 14:42
Return for Revision	2017-04-11 14:45
Revised	2017-04-22 17:47
Second Decision	2017-05-18 03:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-05-19 08:01
Articles in Press	2017-05-19 08:01
Publication Fee Transferred	2017-05-24 06:30
Edit the Manuscript by Language Editor	2017-05-27 07:01
Typeset the Manuscript	2017-06-09 09:28
Publish the Manuscript Online	2017-06-20 12:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation
Manuscript Source	Unsolicited Manuscript
All Author List	Ji-Lai Bian, Mei-Mei Wang, En-Juan Tong, Jing Sun, Ming Li, Zhi-Bo Miao, Yan-Lin Li, Bai-Hong Zhu and Jia-Jia Xu
Funding Agency and Grant Number
Corresponding Author	Dr. Ji-lai Bian, Department of Medical Oncology, The Fifth People's Hospital of Dalian, Dalian 116021, Liaoning Province, China. bianjilai123@126.com
Key Words	Everolimus; Next generation sequencing; PIK3CA; Intrahepatic cholangiocarcinoma
Core Tip	We report a stage IV intrahepatic cholan¬giocarcinoma (ICC) patient harboring a PIK3CA mutation who responded well to the mTOR inhibitor everolimus. Computed tomography and magnetic resonance imaging demonstrated shrinkage of the tumor and the maintenance of partial response for 6.5 mo after everolimus treatment as the best response. To the best of our knowledge, this is the first clinical case report in the literature of an ICC patient with PIK3CA mutation deriving benefit from everolimus treatment.
Publish Date	2017-06-20 12:12
Citation	Bian JL, Wang MM, Tong EJ, Sun J, Li M, Miao ZB, Li YL, Zhu BH, Xu JJ. Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation. World J Gastroenterol 2017; 23(23): 4311-4316
URL	http://www.wjgnet.com/1007-9327/full/v23/i23/4311.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i23.4311

Full Article (PDF)	WJG-23-4311.pdf
Full Article (Word)	WJG-23-4311.doc
Manuscript File	33711-Review.docx
Answering Reviewers	33711-Answering reviewers.pdf
Audio Core Tip	33711-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33711-Conflict-of-interest statement.pdf
Copyright License Agreement	33711-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	33711-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	33711-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	33711-Language certificate.pdf
Peer-review Report	33711-Peer-review(s).pdf
Scientific Misconduct Check	33711-Scientific misconduct check.pdf
Scientific Editor Work List	33711-Scientific editor work list.pdf